title: Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
abstract: OBJECTIVE
  To assess the effects of raloxifene, estrogen, and placebo on quality of life in healthy, asymptomatic, postmenopausal women.
  
  
  METHODS
  In a multicenter, double-blind, 12-month study, 398 women were assigned randomly to one of four groups: raloxifene HCl, 60 (n = 97) or 150 mg/day (n = 100); conjugated equine estrogens, 0. 625 mg/day (n = 96); or placebo (n = 105). The Women's Health Questionnaire, a validated quality-of-life instrument for perimenopausal and postmenopausal women, was administered at baseline and 3-month intervals.
  
  
  RESULTS
  Overall, quality of life from baseline to end point was preserved equally in all treatment groups. Six domains (depressed mood, somatic symptoms, memory/concentration, sexual behavior, sleep problems, and perceived attractiveness) were unchanged in all groups. Three domains (menstrual symptoms, vasomotor symptoms, and anxiety/fears) were statistically significantly different among groups. Mean scores for menstrual symptoms significantly worsened and vasomotor symptoms significantly improved from baseline to end point in the estrogen group. Mean scores for vasomotor symptoms did not worsen at any point in the raloxifene 60 mg/day group. Mean anxiety/fears scores improved significantly during raloxifene 60 mg/day administration throughout treatment (P <.05), irrespective of previous hormone replacement therapy, baseline estradiol (E2) levels, or years postmenopause.
  
  
  CONCLUSIONS
  Most quality-of-life domains were not affected by treatment with estrogen or raloxifene. Estrogen provided relief from vasomotor symptoms but caused menstrual symptoms. Raloxifene 60 mg/day improved anxiety levels in postmenopausal women.
authors.affiliation: Department of Obstetrics and Gynecology, Henry Ford Hospital, Detroit, Michigan, USA.
authors.forename: R
authors.initials: R
authors.lastname: Strickler
authors.forename: D W
authors.initials: DW
authors.lastname: Stovall
authors.forename: D
authors.initials: D
authors.lastname: Merritt
authors.forename: W
authors.initials: W
authors.lastname: Shen
authors.forename: M
authors.initials: M
authors.lastname: Wong
authors.forename: S L
authors.initials: SL
authors.lastname: Silfen
mesh_terms: D002979:Climacteric / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011788:Quality of Life; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D020847:Estrogen Receptor Modulators; D004966:Estrogens, Conjugated (USP); D020849:Raloxifene Hydrochloride